Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 18/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186347 | 0.94 | GRM5 (0.60) | GRM5 | |
| SCHEMBL2188975 | 0.86 | GRM5 (0.55) | GRM5 | |
| SCHEMBL2186516 | 0.84 | CDK2 (0.49) | GRM5 | |
| SCHEMBL12240651 | 0.84 | GRM5 (0.53) | GRM5NPC1ALDH1A1POLBPKM | |
| SCHEMBL2190009 | 0.83 | GRM5 (0.57) | GRM5 | |
| SCHEMBL2174151 | 0.83 | GRM5 (0.61) | GRM5 | |
| SCHEMBL2185127 | 0.83 | GRM5 (0.48) | GRM5 | |
| SCHEMBL2187410 | 0.83 | GRM5 (0.48) | GRM5NPC1PKMRAB9A | |
| SCHEMBL2188928 | 0.83 | GRM5 (0.63) | GRM5 | |
| SCHEMBL2191200 | 0.82 | RIPK1 (0.49) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | GRM5 1/4885NPC1 2788/4885ALDH1A1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.